Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Accumulated Expenses history runs 14 years deep, the most recent figure standing at $38.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 30.25% year-over-year to $38.5 million; the TTM figure through Mar 2026 stood at $38.5 million (up 30.25% YoY), while the FY2025 annual figure was $62.0 million, up 35.6% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $38.5 million, down from $62.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $62.0 million in Q4 2025, with the low at $11.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $24.2 million (2023), against an average of $28.8 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses dropped 9.43% in 2022, then jumped 89.69% in 2024.
• Viridian Therapeutics, Inc.\DE's Accumulated Expenses stood at $18.8 million in 2022, then gained by 28.05% to $24.1 million in 2023, then surged by 89.69% to $45.7 million in 2024, then jumped by 35.6% to $62.0 million in 2025, then tumbled by 37.93% to $38.5 million in 2026.
• Business Quant data shows VRDN's Accumulated Expenses at $38.5 million in Q1 2026, $62.0 million in Q4 2025, and $40.6 million in Q3 2025.